8 results about "Hyocholic acid" patented technology

The invention belongs to the technical field of fish and shrimp breeding feed additives, and particularly relates to a bile acid composition for fish and shrimp feed and a preparation method of the bile acid composition, and the composition comprises the following components in parts by weight: 50-60 parts of hyocholic acid, 40-55 parts of chenodeoxycholic acid, 40-60 parts of hyodeoxycholic acid, 30-45 parts of methionine glycine dipeptide and 60-115 parts of a compound plant extract. According to the invention, the methionine glycine dipeptide is used for improving the lipid metabolism capability of fishes and shrimps; the composite plant extract is used for enhancing the immunity and the anti-stress capability of the fish and the shrimps.

The invention relates to a bile acid mixture in the field of food nutrition supplements and medicines, the bile acid mixture comprises Taurohycholic acid, Taurohycholic acid, Hyocholic acid, Taurohycholic acid, Taurohycholic acid, Taurohycholic acid, Glycholic acid, Chocholic acid, Glycholic acid, 7-Ketoithocholic acid, Glycholic acid and Lithocholic acid, and the bile acid mixture can be used for preventing and treating obesity.

This invention discloses an evaluation method for bile acids in alleviating intestinal inflammation in grouper, belonging to the field of aquaculture technology. Addressing the intestinal inflammation problem caused by feed oxidation, pathogen infection, or water quality deterioration in intensive grouper farming, this invention proposes to achieve efficient regulation of intestinal health by adding a compound bile acid composition to the feed. The core technical solution of the method is as follows: a compound bile acid is formed by compounding porcine deoxycholic acid, chenodeoxycholic acid, and porcine cholic acid in a specific ratio, combined with a carrier premixing process to prepare a bile acid premix, which is then added to the basal feed at 0.15%-0.60% of the total feed mass. This invention effectively alleviates enteritis symptoms in grouper by enhancing the integrity of the intestinal epithelial structure, repairing damaged mucosal barriers, regulating inflammatory responses, and optimizing intestinal flora composition. It provides a safe and efficient technical solution for replacing feed antibiotics in aquaculture, with significant economic and ecological benefits.

The invention discloses a feed additive capable of increasing the laying rate of laying hens and reducing the death and culling rate and application of the feed additive. The feed additive comprises the following components: bile acid, water-soluble starch, glucose, vitamins and composite organic multi-minerals, wherein the bile acid is a mixture prepared from chenodeoxycholic acid, hyodeoxycholic acid and hyocholic acid according to a ratio of 3: 3: 1. The additive is prepared by blending 15-30 parts of bile acid (wherein the ratio of chenodeoxycholic acid to hyodeoxycholic acid to hyocholic acid is 3: 3: 1), 25-35 parts of water-soluble starch, 20-30 parts of glucose, 1-2 parts of vitamins and 2-3 parts of composite organic multi-minerals.

The present application relates to the technical field of diagnostic markers and diagnostic methods for intrahepatic cholestasis of pregnancy (ICP), and in particular to a combination of diagnostic or condition monitoring markers for intrahepatic cholestasis of pregnancy and application thereof. The biomarkers include diagnostic markers for diagnosis and screening, and condition monitoring markers for follow-up; the diagnostic markers include a diagnostic combination marker composed of tauroursodeoxycholic acid and glycochenodeoxycholic acid, and taurohyocholic acid; and the condition monitoring markers include glycochenodeoxycholic acid, glycolcholic acid, and taurohyocholic acid. The technical solution solves the technical problem of the prior art that there is a lack of sensitive and specific diagnostic markers for intrahepatic cholestasis of pregnancy, and has important significance for early diagnosis, auxiliary clinical diagnosis and treatment, and improvement of population quality, and provides a new strategy for the difficult diagnosis and treatment of ICP.

Disclosed in the present invention are a metabolite combination for evaluating the risk of biliary atresia in neonates and a use thereof. The metabolite combination comprises one or more of the following: hyocholic acid, pyroglutamic acid, α-aminobutyric acid, 3-methyl-2-oxovaleric acid and monoconjugated bilirubin, and the metabolite combination cannot only contain one metabolite of monoconjugated bilirubin. The metabolite combination has relatively high correlation with biliary atresia, and has high accuracy, sensitivity and specificity for evaluation of the risk of biliary atresia in neonates.

This invention discloses the application of porcine bile acid components in the preparation of drugs for treating irritable bowel syndrome (IBS-D). The study found that the content of porcine bile acid components in the peripheral feces of IBS-D patients treated with traditional Chinese medicine was significantly increased. Furthermore, compared with a healthy control group, the content of porcine bile acid components in the peripheral fecal samples of IBS-D patients was significantly reduced. Further research revealed that porcine deoxycholic acid and natural traditional Chinese medicine porcine bile powder can significantly improve diarrhea and abdominal pain symptoms in TNBS-induced mice by inhibiting tryptophan hydroxylase 1 activity and reducing peripheral serotonin levels. This invention suggests the application value of porcine bile acid components in the treatment of IBS-D.

The present invention discloses use of hyocholic acid (HCA)-based bile acid species in the preparation of a medicament for the treatment of irritable bowel syndrome (IBS). It was discovered in the present invention that the content of HCA species in the feces of IBS-D patients treated with traditional Chinese medicine was significantly increased. Moreover, HCA species were significantly reduced in fecal samples of IBS-D patients compared with healthy controls. Further research revealed that HDCA and natural traditional Chinese medicine PULVIS FELLIS SUIS can reduce the peripheral serotonin level by inhibiting the activity of tryptophan hydroxylase 1, and significantly improve the symptoms of diarrhea and abdominal pain in TNBS-induced mice, indicating an application value of HCA species in treating IBS-D.